EE200100125A - TAN-1057 derivaadid - Google Patents

TAN-1057 derivaadid

Info

Publication number
EE200100125A
EE200100125A EEP200100125A EEP200100125A EE200100125A EE 200100125 A EE200100125 A EE 200100125A EE P200100125 A EEP200100125 A EE P200100125A EE P200100125 A EEP200100125 A EE P200100125A EE 200100125 A EE200100125 A EE 200100125A
Authority
EE
Estonia
Prior art keywords
derivatives
tan
disorders
humans
animals
Prior art date
Application number
EEP200100125A
Other languages
English (en)
Estonian (et)
Inventor
Brands Michael
Es-Sayed Mazen
H�bich Dieter
Raddatz Siegfried
Kr�ger Joachim
Endermann Rainer
Gahlmann Reinhold
Kroll Hein-Peter
Geschke Frank-Ulrich
De Meijere Armin
N. Belov Vladimir
Sokolov Victor
Kozhushkov Sergej
Kordes Markus
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of EE200100125A publication Critical patent/EE200100125A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/48Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
EEP200100125A 1998-08-27 1999-08-20 TAN-1057 derivaadid EE200100125A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19838998A DE19838998A1 (de) 1998-08-27 1998-08-27 Neue Naturstoffderivate
PCT/EP1999/006124 WO2000012484A1 (de) 1998-08-27 1999-08-20 Tan-1057 derivate

Publications (1)

Publication Number Publication Date
EE200100125A true EE200100125A (et) 2002-06-17

Family

ID=7878913

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100125A EE200100125A (et) 1998-08-27 1999-08-20 TAN-1057 derivaadid

Country Status (25)

Country Link
US (1) US6617332B1 (sk)
EP (1) EP1117652B1 (sk)
JP (1) JP4533535B2 (sk)
KR (1) KR20010099629A (sk)
CN (1) CN1324348A (sk)
AT (1) ATE267816T1 (sk)
AU (1) AU759618B2 (sk)
BG (1) BG105275A (sk)
BR (1) BR9913337A (sk)
CA (1) CA2342102C (sk)
DE (2) DE19838998A1 (sk)
EE (1) EE200100125A (sk)
ES (1) ES2219105T3 (sk)
HK (1) HK1041884A1 (sk)
HR (1) HRP20010135A2 (sk)
HU (1) HUP0103316A3 (sk)
ID (1) ID28365A (sk)
IL (1) IL141325A0 (sk)
NO (1) NO20010940L (sk)
NZ (1) NZ510153A (sk)
PL (1) PL346143A1 (sk)
SK (1) SK2622001A3 (sk)
TR (1) TR200100637T2 (sk)
WO (1) WO2000012484A1 (sk)
ZA (1) ZA200101038B (sk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113008A1 (en) * 1999-12-29 2001-07-04 Pfizer Products Inc. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
EP2599781A1 (en) * 2007-12-20 2013-06-05 Dr. Reddy's Laboratories Ltd. Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2011046007A1 (ja) 2009-10-15 2011-04-21 国立大学法人徳島大学 ジエチレントリアミン五酢酸誘導体の製造方法およびジエチレントリアミン五酢酸誘導体
MX339000B (es) 2009-10-16 2016-05-09 Melinta Therapeutics Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
JP6267863B2 (ja) 2009-10-16 2018-01-24 メリンタ セラピューティクス,インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
CN108456211A (zh) * 2009-10-16 2018-08-28 梅琳塔治疗公司 抗微生物化合物和其制备和使用方法
KR20180051676A (ko) 2009-10-16 2018-05-16 멜린타 테라퓨틱스, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
PT2697229T (pt) 2011-04-15 2018-04-13 Melinta Therapeutics Inc Compostos antimicrobianos e seus métodos de fabrico e de utilização
RU2475479C1 (ru) * 2011-12-23 2013-02-20 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Вазоконстрикторное средство
CA2923179A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CA2923214A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3268370A4 (en) 2015-03-11 2018-08-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
WO1999007685A1 (en) 1997-08-07 1999-02-18 Research Corporation Technologies, Inc. Antibiotic for methicillin resistant bacteria

Also Published As

Publication number Publication date
EP1117652A1 (de) 2001-07-25
BG105275A (en) 2001-11-30
DE19838998A1 (de) 2000-03-09
CA2342102C (en) 2008-10-28
US6617332B1 (en) 2003-09-09
HK1041884A1 (zh) 2002-07-26
ES2219105T3 (es) 2004-11-16
BR9913337A (pt) 2001-05-15
IL141325A0 (en) 2002-03-10
NO20010940L (no) 2001-04-23
CN1324348A (zh) 2001-11-28
TR200100637T2 (tr) 2001-10-22
NZ510153A (en) 2002-12-20
CA2342102A1 (en) 2000-03-09
KR20010099629A (ko) 2001-11-09
SK2622001A3 (en) 2001-11-06
HUP0103316A3 (en) 2002-06-28
ATE267816T1 (de) 2004-06-15
JP2002523496A (ja) 2002-07-30
JP4533535B2 (ja) 2010-09-01
ID28365A (id) 2001-05-17
EP1117652B1 (de) 2004-05-26
NO20010940D0 (no) 2001-02-23
HRP20010135A2 (en) 2002-02-28
PL346143A1 (en) 2002-01-28
AU759618B2 (en) 2003-04-17
AU1009900A (en) 2000-03-21
DE59909607D1 (de) 2004-07-01
HUP0103316A2 (hu) 2002-04-29
WO2000012484A1 (de) 2000-03-09
ZA200101038B (en) 2002-02-07

Similar Documents

Publication Publication Date Title
MY124122A (en) Heterocyclic derivatives
DK1200418T3 (da) Nematodicide trifluorbutener
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
GB9715894D0 (en) Heterocyclic derivatives
MY115211A (en) Novel amino acid derivatives, their preparation and use
NO20010940L (no) TAN-1057 derivater
BG106155A (en) Novel derivatives and analogues of galanthamin
GB9809349D0 (en) Heterocyclic derivatives
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
MXPA04005552A (es) Analogos de vitamina d.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE69402004T2 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
PT1232173E (pt) Derivados do acido fusidico
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas
SE9803277D0 (sv) Novel compounds
DK0580624T3 (da) Hidtil ukendte cytarabinderivater, fremstilling og anvendelse deraf
GB9926301D0 (en) Novel compounds
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors